Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Stopped early · Not applicable
Conditions studied: Glaucoma, Ocular Hypertension, Open Angle Glaucoma
In brief
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
Key facts
- Study ID
- NCT05273385
- Run by
- University of California, San Francisco
- People needed
- 16
- Starts
- 2022-10-10
- Expected to finish
- 2024-12-10
- Last updated by the study team
- 2026-03-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years old or older
- Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
- Use of prostaglandin analogue (PGA) eye drop
- Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)
You may not qualify if…
- Uncontrolled glaucoma
- Have had eye surgery (including laser procedures) within the past six months
- Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
- Use of non-PGA class of IOP-lowering medication
Where it is running
- University of California, San Francisco — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.